Delineating HIV-associated neurocognitive disorders using transgenic models: The neuropathogenic actions of Vpr

Journal of Neuroimmune Pharmacology

Volumn 7, Issue 2, 2012, Pages 319-331

  Power, Christopher ^a   Hui, Elizabeth ^a   Vivithanaporn, Pornpun ^a,b   Acharjee, Shaona ^a   Polyak, Maria ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Dementia; HIV 1; Neuropathogenesis; Transgenic mouse; Vpr

Indexed keywords

ANTIRETROVIRUS AGENT; C FMS PROTEIN; CASPASE 3; CASPASE 6; CASPASE 9; CORE PROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VPR PROTEIN; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

APOPTOSIS; ASTROCYTE; BONE MARROW CELL; BRAIN; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL DEATH; CELL TYPE; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISABILITY; DISEASE ASSOCIATION; GENE EXPRESSION; HEPATITIS C VIRUS; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; TARGET CELL; TRANSGENIC ANIMAL; VIRUS LOAD; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM; PATHOGENICITY; VIROLOGY;

AIDS DEMENTIA COMPLEX; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; HIV-1; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84866479042     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-011-9310-7     Document Type: Review

References (114)

1. Acharjee S, Noorbakhsh F, Stemkowski PL, Olechowski C, Cohen EA, Ballanyi K, Kerr B, Pardo C, Smith PA, Power C (2010) HIV-1 viral protein R causes peripheral nervous system injury \associated with in vivo neuropathic pain. FASEB J 24:4343-4353
2. Agostini I, Navarro JM, Rey F, Bouhamdan M, Spire B, Vigne R, Sire J (1996) The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB. J Mol Biol 261:599-606 (Pubitemid 26300794)
3. Ahn J, Vu T, Novince Z, Guerrero-Santoro J, Rapic-Otrin V, Gronenborn AM (2010) HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation. J Biol Chem 285:37333-37341
4. Alter MJ (2006) Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44:S6-S9 (Pubitemid 43053865)
5. Andrew A, Strebel K (2010) HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Mol Asp Med 31:407-417
6. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, GisslenM, Grant I, HeatonRK, Joseph J, Marder K,MarraCM,McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789-1799 (Pubitemid 350059308)
7. Antony JM, Ellestad KK, Hammond R, Imaizumi K, Mallet F, Warren KG, Power C (2007) The human endogenous retrovirus envelope glycoprotein, syncytin-1, regulates neuroinflammation and its receptor expression in multiple sclerosis: a role for endoplasmic reticulum chaperones in astrocytes. J Immunol 179:1210-1224
8. Basavapathruni A, Anderson KS (2007) Reverse transcription of the HIV-1 pandemic. FASEB J 21:3795-3808 (Pubitemid 350232337)
9. Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, Cohen EA (2007) HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog 3:e85
10. Belzile JP, Abrahamyan LG, Gerard FC, Rougeau N, Cohen EA (2010) Formation of mobile chromatin-associated nuclear foci containing HIV-1 Vpr and VPRBP is critical for the induction of G2 cell cycle arrest. PLoS Pathog 6:e1001080
11. Bhalerao J, Bogers J, Van Marck E, Merregaert J (1995) Establishment and characterization of two clonal cell lines derived from murine mandibular condyles. Tissue Cell 27:369-382
12. Boisse L, Gill MJ, Power C (2008) HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin 26:799-819, x
13. Browning Paul J, Wang EJ, Pettoello-Mantovani M, Raker C, Yurasov S, Goldstein MM, Horner JW, Chan J, Goldstein H (2000) Mice transgenic for monocyte-tropic HIV type 1 produce infectious virus and display plasma viremia: a new in vivo system for studying the postintegration phase of HIV replication. AIDS Res Hum Retrovir 16:481-492 (Pubitemid 30193816)
14. Chen R, Wang H, Mansky LM (2002) Roles of uracil-DNA glycosylase and dUTPase in virus replication. J Gen Virol 83:2339-2345
15. Cheng X, Mukhtar M, Acheampong EA, Srinivasan A, Rafi M, Pomerantz RJ, Parveen Z (2007) HIV-1 Vpr potently induces programmed cell death in the CNS in vivo. DNA Cell Biol 26:116-131 (Pubitemid 46363877)
16. Connor RI, Chen BK, Choe S, Landau NR (1995) Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944
17. Corboy JR, Buzy JM, Zink MC, Clements JE (1992) Expression directed from HIV long terminal repeats in the central nervous system of transgenic mice. Science 258:1804-1808 (Pubitemid 23087350)
18. Deacon RM, Rawlins JN (2006) T-maze alternation in the rodent. Nat Protoc 1:7-12
19. DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, Planelles V (2007) HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 4:57
20. Dickie P, Roberts A, Uwiera R, Witmer J, Sharma K, Kopp JB (2004) Focal glomerulosclerosis in proviral and c-fms transgenic mice links Vpr expression to HIV-associated nephropathy. Virology 322:69-81 (Pubitemid 38519870)
21. Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale M Jr (2009) Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol 83:10395-10405
22. Dube M, Bego MG, Paquay C, Cohen EA (2010) Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology 7:114
23. Evans DT, Serra-Moreno R, Singh RK, Guatelli JC (2010) BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol 18:388-396
24. Felzien LK, Woffendin C, Hottiger MO, Subbramanian RA, Cohen EA, Nabel GJ (1998) HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator.Proc Natl Acad Sci USA 95:5281-5286 (Pubitemid 28208589)
25. Ferrari S, Vento S, Monaco S, Cavallaro T, Cainelli F, Rizzuto N, Temesgen Z (2006) Human immunodeficiency virus-associated peripheral neuropathies. Mayo Clin Proc 81:213-219 (Pubitemid 43205776)
26. Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, Nowak MA, Hahn BH, Emerman M (1998) HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med 4:65-71 (Pubitemid 28133081)
27. Gonzalez VD, Landay AL, Sandberg JK (2010) Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol 135:12-25
28. Gonzalez-Duarte A, Cikurel K, Simpson DM (2007) Managing HIV peripheral neuropathy. Curr HIV/AIDS Rep 4:114-118 (Pubitemid 47493051)
29. Gonzalez-Duarte A, Sullivan S, Sips GJ, Naidich T, Kleinman G, Murray J, Morgello S, Germano I, Mullen M, Simpson D (2009) Inflammatory pseudotumor associated with HIV, JCV, and immune reconstitution syndrome. Neurology 72:289-290
30. Gonzalez-Scarano F, Martin-Garcia J (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5:69-81 (Pubitemid 40070332)
31. Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, Birch CJ, Bell JE, Bannert N, Crawford K, Wang H, Schols D, De Clercq E, Kunstman K, Wolinsky SM, Gabuzda D (2001) Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol 75:10073-10089 (Pubitemid 32948038)
32. Goudreau G, Carpenter S, Beaulieu N, Jolicoeur P (1996) Vacuolar myelopathy in transgenic mice expressing human immunodeficiency virus type 1 proteins under the regulation of the myelin basic protein gene promoter. Nat Med 2:655-661 (Pubitemid 26191952)
33. Gras G, Kaul M (2010) Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology 7:30
34. Guyader M, Emerman M, Montagnier L, Peden K (1989) VPX mutants of HIV-2 are infectious in established cell lines but display a severe defect in peripheral blood lymphocytes. EMBO J 8:1169-1175 (Pubitemid 19273285)
35. Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, Jolicoeur P (1998) Nef harbors a major determinant of pathogenicity for an AIDSlike disease induced by HIV-1 in transgenic mice. Cell 95:163-175 (Pubitemid 28473778)
36. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69:6705-6711
37. Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman HE, Ratner L, Stevenson M, Emerman M (1994) The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 91:7311-7315 (Pubitemid 24226853)
38. Hogan TH, Nonnemacher MR, Krebs FC, Henderson A, Wigdahl B (2003) HIV-1 Vpr binding to HIV-1 LTR C/EBP cis-acting elements and adjacent regions is sequence-specific. Biomed Pharmacother 57:41-48 (Pubitemid 36315669)
39. Huang MB, Weeks O, Zhao LJ, Saltarelli M, Bond VC (2000) Effects of extracellular human immunodeficiency virus type 1 vpr protein in primary rat cortical cell cultures. J Neurovirol 6:202-220 (Pubitemid 30447165)
40. Jacotot E, Ravagnan L, Loeffler M, Ferri KF, Vieira HL, Zamzami N, Costantini P, Druillennec S, Hoebeke J, Briand JP, Irinopoulou T, Daugas E, Susin SA, Cointe D, Xie ZH, Reed JC, Roques BP, Kroemer G (2000) The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 191:33-46
41. Jacotot E, Ferri KF, El Hamel C, Brenner C, Druillennec S, Hoebeke J, Rustin P, Metivier D, Lenoir C, Geuskens M, Vieira HL, Loeffler M, Belzacq AS, Briand JP, Zamzami N, Edelman L, Xie ZH, Reed JC, Roques BP, Kroemer G (2001) Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med 193:509-519 (Pubitemid 32524481)
42. Johnson T, Nath A (2011) Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol 24:284-290
43. Jones G, Power C (2006) Regulation of neural cell survival by HIV-1 infection. Neurobiol Dis 21:1-17 (Pubitemid 41817300)
44. Jones GJ, Barsby NL, Cohen EA, Holden J, Harris K, Dickie P, Jhamandas J, Power C (2007) HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci 27:3703-3711 (Pubitemid 46557688)
45. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS (1995) The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2+M phase of the cell cycle. J Virol 69:6304-6313
46. Keswani SC, Jack C, Zhou C, Hoke A (2006) Establishment of a rodent model of HIV-associated sensory neuropathy. J Neurosci 26:10299-10304 (Pubitemid 44527423)
47. Kim BO, Liu Y, Ruan Y, Xu ZC, Schantz L, He JJ (2003) Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol 162:1693-1707 (Pubitemid 36512853)
48. Kim HE, Du F, Fang M, Wang X (2005) Formation of apoptosome is initiated by cytochrome c-induced dATP hydrolysis and subsequent nucleotide exchange on Apaf-1. Proc Natl Acad Sci USA 102:17545-17550 (Pubitemid 41803534)
49. Kitayama H, Miura Y, Ando Y, Hoshino S, Ishizaka Y, Koyanagi Y (2008) Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction. J Virol 82:2528-2542 (Pubitemid 351293553)
50. Kondo E, Gottlinger HG (1996) A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr. J Virol 70:159-164 (Pubitemid 126508781)
51. Kondo E, Mammano F, Cohen EA, Gottlinger HG (1995) The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J Virol 69:2759-2764
52. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M (2011) SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474(7353):654-657
53. Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, Transy C, Margottin-Goguet F (2007) HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 6:182-188 (Pubitemid 46232499)
54. Le Rouzic E, Morel M, Ayinde D, Belaidouni N, Letienne J, Transy C, Margottin-Goguet F (2008) Assembly with the Cul4ADDB1DCAF1 ubiquitin ligase protects HIV-1 Vpr from proteasomal degradation. J Biol Chem 283:21686-21692
55. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ (2008) Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65-70
56. Levy DN, Refaeli Y, MacGregor RR, Weiner DB (1994) Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 91:10873-10877 (Pubitemid 24349587)
57. Lu YL, Spearman P, Ratner L (1993) Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virol 67:6542-6550 (Pubitemid 23309120)
58. Mansky LM (1996) The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology 222:391-400 (Pubitemid 26279184)
59. Mansky LM, Preveral S, Selig L, Benarous R, Benichou S (2000) The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate. J Virol 74:7039-7047 (Pubitemid 30470687)
60. McArthur JC, Brew BJ, Nath A (2005) Neurological complications of HIV infection. Lancet Neurol 4:543-555 (Pubitemid 41139976)
61. Morellet N, Bouaziz S, Petitjean P, Roques BP (2003) NMR structure of the HIV-1 regulatory protein VPR. J Mol Biol 327:215-227 (Pubitemid 36293314)
62. Muller B, Tessmer U, Schubert U, Krausslich HG (2000) Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than gag and is phosphorylated in infected cells. J Virol 74:9727-9731
63. Murray AW (1992) Creative blocks: cell-cycle checkpoints and feedback controls. Nature 359:599-604
64. Na H, Acharjee S, Jones G, Vivithanaporn P, Noorbakhsh F, McFarlane N, Maingat F, Ballanyi K, Pardo C, Cohen EA, Power C (2011) Interactions between human immunodeficiency virus (HIV)-1 Vpr expression and innate immunity influence neurovirulence. Retrovirology 8:44
65. Nandy P, Banerjee S, Gao H, Hui MB, Lien EJ (1991) Quantitative structure-activity relationship analysis of combretastatins: a class of novel antimitotic agents. Pharm Res 8:776-781
66. Noorbakhsh F, Tang Q, Liu S, Silva C, van Marle G, Power C (2006) Lentivirus envelope protein exerts differential neuropathogenic effects depending on the site of expression and target cell. Virology 348:260-276
67. Noorbakhsh F, Overall CM, Power C (2009) Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Trends Neurosci 32:88-100
68. Noorbakhsh F, Ramachandran R, Barsby N, Ellestad KK, LeBlanc A, Dickie P, Baker G, Hollenberg MD, Cohen EA, Power C (2010) MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival. FASEB J 24:1799-1812
69. Ohagen A, Ghosh S, He J, Huang K, Chen Y, Yuan M, Osathanondh R, Gartner S, Shi B, Shaw G, Gabuzda D (1999) Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: evidence for a role of the envelope. J Virol 73:897-906 (Pubitemid 29036740)
70. Okumura A, Alce T, Lubyova B, Ezelle H, Strebel K, Pitha PM (2008) HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 373:85-97
71. Pancio HA, Vander Heyden N, Ratner L (2000) The C-terminal proline-rich tail of human immunodeficiency virus type 2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells. J Virol 74:6162-6167 (Pubitemid 30412988)
72. Pandya R, Krentz HB, Gill MJ, Power C (2005) HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci 32:201-204 (Pubitemid 40839962)
73. Parikh SS, Walcher G, Jones GD, Slupphaug G, Krokan HE, Blackburn GM, Tainer JA (2000) Uracil-DNA glycosylase-DNA substrate and product structures: conformational strain promotes catalytic efficiency by coupled stereoelectronic effects. Proc Natl Acad Sci USA 97:5083-5088 (Pubitemid 30313675)
74. Patel CA, Mukhtar M, Pomerantz RJ (2000) Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol 74:9717-9726
75. Piller SC, Ewart GD, Jans DA, Gage PW, Cox GB (1999) The aminoterminal region of Vpr from human immunodeficiency virus type 1 forms ion channels and kills neurons. J Virol 73:4230-4238 (Pubitemid 29189868)
76. Power C, McArthur JC, Johnson RT, Griffin DE, Glass JD, Perryman S, Chesebro B (1994) Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol 68:4643-4649 (Pubitemid 24183062)
77. Power C, McArthur JC, Nath A, Wehrly K, Mayne M, Nishio J, Langelier T, Johnson RT, Chesebro B (1998) Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol 72:9045-9053 (Pubitemid 28471848)
78. Power C, Boisse L, Rourke S, Gill MJ (2009) NeuroAIDS: an evolving epidemic. Can J Neurol Sci 36:285-295
79. Re F, Braaten D, Franke EK, Luban J (1995) Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol 69:6859-6864
80. Reid W, Sadowska M, Denaro F, Rao S, Foulke J Jr, Hayes N, Jones O, Doodnauth D, Davis H, Sill A, O'Driscoll P, Huso D, Fouts T, Lewis G, Hill M, Kamin-Lewis R, Wei C, Ray P, Gallo RC, Reitz M, Bryant J (2001) An HIV-1 transgenic rat that develops HIVrelated pathology and immunologic dysfunction. Proc Natl Acad Sci USA 98:9271-9276 (Pubitemid 32743906)
81. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, Fuller JC, Jackson RM, Lamb T, Briggs TA, Ali M, Gornall H, Couthard LR, Aeby A, Attard-Montalto SP, Bertini E, Bodemer C, Brockmann K, Brueton LA, Corry PC, Desguerre I, Fazzi E, Cazorla AG, Gener B, Hamel BC, Heiberg A, Hunter M, van der Knaap MS, Kumar R, Lagae L, Landrieu PG, Lourenco CM, Marom D, McDermott MF, van der Merwe W, Orcesi S, Prendiville JS, Rasmussen M, Shalev SA, Soler DM, Shinawi M, Spiegel R, Tan TY, Vanderver A, Wakeling EL, Wassmer E, Whittaker E, Lebon P, Stetson DB, Bonthron DT, Crow YJ (2009) Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 41:829-832
82. Rogel ME, Wu LI, Emerman M (1995) The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 69:882-888
83. Romani B, Engelbrecht S (2009) Human immunodeficiency virus type 1 Vpr: functions and molecular interactions. J Gen Virol 90:1795-1805
84. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC (2001) HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990-1998. Neurology 56:257-260 (Pubitemid 32095372)
85. Schuler W, Wecker K, de Rocquigny H, Baudat Y, Sire J, Roques BP (1999) NMR structure of the (52-96) C-terminal domain of the HIV-1 regulatory protein Vpr: molecular insights into its biological functions. J Mol Biol 285:2105-2117 (Pubitemid 29078174)
86. Si Q, Kim MO, Zhao ML, Landau NR, Goldstein H, Lee S (2002) Vpr- and Nef-dependent induction of RANTES/CCL5 in microglial cells. Virology 301:342-353 (Pubitemid 35176558)
87. Smit TK, Wang B, Ng T, Osborne R, Brew B, Saksena NK (2001) Varied tropism of HIV-1 isolates derived from different regions of adult brain cortex discriminate between patients with and without AIDS Dementia Complex (ADC): evidence for neurotropic HIV variants. Virology 279:509-526 (Pubitemid 34161115)
88. Solomon MJ, Glotzer M, Lee TH, Philippe M, Kirschner MW (1990) Cyclin activation of p34cdc2. Cell 63:1013-1024
89. Srivastava S, Swanson SK, Manel N, Florens L, Washburn MP, Skowronski J (2008) Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog 4:e1000059
90. Stewart SA, Poon B, Jowett JB, Chen IS (1997) Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol 71:5579-5592 (Pubitemid 27258237)
91. Strebel K, Luban J, Jeang KT (2009) Human cellular restriction factors that target HIV-1 replication. BMC Med 7:48
92. Sun J, Zheng JH, Zhao M, Lee S, Goldstein H (2008) Increased in vivo activation of microglia and astrocytes in the brains of mice transgenic for an infectious R5 human immunodeficiency virus type 1 provirus and for CD4-specific expression of human cyclin T1 in response to stimulation by lipopolysaccharides. J Virol 82:5562-5572 (Pubitemid 351705263)
93. Tan L, Ehrlich E, Yu XF (2007) DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol 81:10822-10830 (Pubitemid 47463356)
94. Thein HH, Yi Q, Dore GJ, Krahn MD (2008) Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 22:1979-1991
95. Thomas FP, Chalk C, Lalonde R, Robitaille Y, Jolicoeur P (1994) Expression of human immunodeficiency virus type 1 in the nervous system of transgenic mice leads to neurological disease. J Virol 68:7099-7107 (Pubitemid 24328761)
96. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L (1994) Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice [see comments]. Nature 367:188-193 (Pubitemid 24031702)
97. Tristem M, Purvis A, Quicke DL (1998) Complex evolutionary history of primate lentiviral vpr genes. Virology 240:232-237 (Pubitemid 28384229)
98. Venkatachari NJ, Walker LA, Tastan O, Le T, Dempsey TM, Li Y, Yanamala N, Srinivasan A, Klein-Seetharaman J, Montelaro RC, Ayyavoo V (2010) Human immunodeficiency virus type 1 Vpr: oligomerization is an essential feature for its incorporation into virus particles. Virol J 7:119
99. Vergote D, Butler GS, Ooms M, Cox JH, Silva C, Hollenberg MD, Jhamandas JH, Overall CM, Power C (2006) Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegeneration. Proc Natl Acad Sci USA 103:19182-19187 (Pubitemid 350002847)
100. Vivithanaporn P, Maingat F, Lin LT, Na H, Richardson CD, Agrawal B, Cohen EA, Jhamandas JH, Power C (2010) Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity. PLoS One 5:e12856
101. Wecker K, Roques BP (1999) NMR structure of the (1-51) N-terminal domain of the HIV-1 regulatory protein Vpr. Eur J Biochem 266:359-369
102. Wedemeyer H (2011) Hepatitis D revival. Liver Int 31(Suppl 1):140-144
103. Wen X, Duus KM, Friedrich TD, de Noronha CM (2007) The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J Biol Chem 282:27046-27057
104. Wheeler ED, Achim CL, Ayyavoo V (2006) Immunodetection of human immunodeficiency virus type 1 (HIV-1) Vpr in brain tissue of HIV-1 encephalitic patients. J Neurovirol 12:200-210 (Pubitemid 44574595)
105. Wilkinson J, Radkowski M, Laskus T (2009) Hepatitis C virus neuroinvasion: identification of infected cells. J Virol 83:1312-1319
106. Wilkinson J, Radkowski M, Eschbacher JM, Laskus T (2010) Activation of brain macrophages/microglia cells in hepatitis C infection. Gut 59:1394-1400
107. Yadav A, Collman RG (2009) CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J Neuroimmune Pharmacol 4:430-447
108. Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, Cohen EA (1995) Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alphahelical structure in Vpr nuclear localization and virion incorporation. J Virol 69:7032-7044
109. Yeung H, Krentz HB, Gill MJ, Power C (2006) Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care. AIDS 20:2005-2009 (Pubitemid 44611053)
110. Yu XF, Yu QC, Essex M, Lee TH (1991) The vpx gene of simian immunodeficiency virus facilitates efficient viral replication in fresh lymphocytes and macrophage. J Virol 65:5088-5091
111. Zhang K, Kaufman RJ (2008) From endoplasmic-reticulum stress to the inflammatory response. Nature 454:455-462
112. Zhang K, McQuibban GA, Silva C, Butler GS, Johnston JB, Holden J, Clark-Lewis I, Overall CM, Power C (2003) HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci 6:1064-1071 (Pubitemid 37186198)
113. Zhao RY, Li G, Bukrinsky MI (2011) Vpr-host interactions during HIV-1 viral life cycle. J Neuroimmune Pharmacol 6:216-229
114. Zhu Y, Vergote D, Pardo C, Noorbakhsh F, McArthur JC, Hollenberg MD, Overall CM, Power C (2009) CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy. FASEB J 23:2928-2941